Top

Published in:

Open Access 01-02-2021 | Gastrostomy | Commentary

Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience

Authors: Martina Budel, Luca Martella, Laura Zambon, Isabella Morson, Giorgio Giorda, Renato Cannizzaro

Published in: Supportive Care in Cancer | Issue 2/2021

Abstract

The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA A Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590CrossRef

Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2013) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. Obstet Gynecol Surv 68(6):437–438CrossRef

Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, Barakat RR (2005) Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96(2):330–334CrossRef

Campagnutta E, Cannizzaro R, Gallo A, Zarrelli A, Valentini M, de Cicco M, Scarabelli C (1996) Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol 62(1):103–105. https://doi.org/10.1006/gyno.1996.0197CrossRefPubMed

Clarke-Pearson DL, Chin NO, DeLong ER, Rice R, Creasman WT (1987) Surgical management of intestinal obstruction in ovarian cancer: I. Clinical features, postoperative complications, and survival. Gynecol Oncol 26(1):11–18CrossRef

Cannizzaro R, Bortoluzzi F, Valentini M, Scarabelli C, Campagnutta E, Sozzi M, Fornasarig M, Poletti M (1995) Percutaneous endoscopic gastrostomy as a decompressive technique in bowel obstruction due to abdominal carcinomatosis. Endoscopy 27(04):317–320CrossRef

Scheidbach H, Horbach T, Groitl H, Hohenberger W (1999) Percutaneous endoscopic gastrostomy/jejunostomy (PEG/PEJ) for decompression in the upper gastrointestinal tract. Surg Endosc 13(11):1103–1105CrossRef

Zucchi E, Fornasarig M, Martella L, Maiero S, Lucia E, Borsatti E, Balestreri L, Giorda G, Annunziata MA, Cannizzaro R (2016) Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study. Support Care Cancer 24(7):2877–2882PubMed

Gauderer MWL (2001) Percutaneous endoscopic gastrostomy—20 years later: a historical perspective. J Pediatr Surg 36(1):217–219CrossRef

10.

Giustina A et al (2001) Somatostatin analogues: clinical pharmacology and new trends, chapter Therapeutic Aspects, 1–12. Ipsen.

11.

Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A (1996) Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 61(3):345–348CrossRef

12.

Campagnutta E, Cannizzaro R, de Cicco M, de Piero G, Giorda G, Sopracordevole F, Parin A, Scarabelli C (1998) La gastrostomia percutanea endoscopica (PEG) nelle occlusioni dell’alto tratto intestinale in ginecologia oncologica [Percutaneous endoscopic gastrostomy (PEG) in upper gastrointestinal tract occlusion in gynecologic oncology]. Minerva Ginecol 50(7-8):305–311PubMed

Title: Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience
Authors: Martina Budel
Luca Martella
Laura Zambon
Isabella Morson
Giorgio Giorda
Renato Cannizzaro
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Gastrostomy
Ovarian Cancer
Ovarian Cancer
Gynecologic Cancer
Peritoneal Cancer
Peritoneal Carcinomatosis
Published in: Supportive Care in Cancer / Issue 2/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05745-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Opportunities for pharmacogenomics-guided supportive care in cancer

Correction to: Pre-post analysis of a social capital-based exercise adherence intervention for breast cancer survivors with moderate fatigue: a randomized controlled trial

Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper

How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study

Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer

Protein intake, weight loss, dietary intervention, and worsening of quality of life in older patients during chemotherapy for cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer